Concepedia

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

Grant A. McArthur, Michele Maio, Ana Arance, Paul Nathan, Christian U. Blank, Marie‐Françoise Avril, Claus Garbe, Axel Hauschild, Dirk Schadendorf, Omid Hamid,

Annals of Oncology · 2016 · 246 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +16

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +16

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

, , +7

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Kim Margolin, Marc S. Ernstoff, Omid Hamid et al. · The Lancet Oncology · 2012 · 1.1K citations

, , +12

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 978 citations

, , +13